Breaking News

Financial Report: AbbVie

July 25, 2014

Humira sales up 10% in the quarter


2Q Revenues: $4.9 billion (+5%)

2Q Earnings: $1.1 billion (+3%)

YTD Revenues: $9.5 billion (+5%)

YTD Earnings: $2.1 billion (+2%)

Comments: Humira sales were up 10% to $3.3 billion in the quarter. AndroGel sales reached $218 million. Synthroid ($166 million), Sevoflurane ($154 million, +11%) and Duodopa ($56 million, +29%) also performed well in the quarter. Kaletra sales dropped 24% to $216 million and Lupron sales were down 3% to $186 million. The company recently announced plans to merge with Shire, creating a larger and more diversified biopharma company with multiple leading franchises.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks